Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
ChinaIPO:
12 June 1996Next earnings report:
14 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 01 Nov 2024 20:00:00 GMTDividend
Analysts recommendations
Institutional Ownership
CASI Latest News
BEIJING , Sept. 4, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today announced its participation in the H.C.
BEIJING , Aug. 16, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended June 30, 2024. "The second quarter of 2024 was a period of significant progress for CASI as we shifted our Company's strategy to the development of therapeutics for organ transplant rejection and autoimmune disease," said Dr. Wei-Wu He, Chairman and CEO of CASI Pharmaceuticals.
What could be better than viable enterprises within the biotechnology industry? Try biotech stocks under $10.
BEIJING , July 19, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas. For details, please visit below link: https://www.sec.gov/Archives/edgar/data/1962738/000110465924080958/tm2419826d1_6k.htm About CASI Pharmaceuticals CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world.
BEIJING , July 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces appointment of Daniel Lang, MD as Chief Financial Officer and Senior Vice President, effective July 8 th, 2024. Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive.
CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.
What type of business is CASI Pharmaceuticals?
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
What sector is CASI Pharmaceuticals in?
CASI Pharmaceuticals is in the Healthcare sector
What industry is CASI Pharmaceuticals in?
CASI Pharmaceuticals is in the Biotechnology industry
What country is CASI Pharmaceuticals from?
CASI Pharmaceuticals is headquartered in China
When did CASI Pharmaceuticals go public?
CASI Pharmaceuticals initial public offering (IPO) was on 12 June 1996
What is CASI Pharmaceuticals website?
https://www.casipharmaceuticals.com
Is CASI Pharmaceuticals in the S&P 500?
No, CASI Pharmaceuticals is not included in the S&P 500 index
Is CASI Pharmaceuticals in the NASDAQ 100?
No, CASI Pharmaceuticals is not included in the NASDAQ 100 index
Is CASI Pharmaceuticals in the Dow Jones?
No, CASI Pharmaceuticals is not included in the Dow Jones index
When was CASI Pharmaceuticals the previous earnings report?
No data
When does CASI Pharmaceuticals earnings report?
The next expected earnings date for CASI Pharmaceuticals is 14 November 2024